OpenText process and document management solutions for pharmaceutical & life sciences conference

13 - 14 May 2013, Kassel, Germany.
OpenText solutions for the Pharmaceutical and Life Sciences industries support critical processes where compliant management of all paper and electronic records and documents is essential. You are invited to attend the Comprehensive Process and Document Management Life Science Conference held in Kassel, Germany. Join this conference to learn about the GxP Compliance, Document Management in CMC, Computer System Validation and other topics with the "Ask the Experts" session.

Get an Free Onsite Visit at B. Braun in Melsungen and watch how B. Braun made the switch from EMC Documentum to OpenText Regulated Documents.

OpenText will present for the first time the newest Solutions for Business Process Management "ASSURE for Regulated Documents" on this conference.

Visit this life science event and get an onsite visit at B. Braun in Melsungen (Germany) for free and have an "Ask the Experts" session on the 13th May. The onsite visit includes as well the networking dinner.

Follow this link and register today for the free "Onsite Visit" at B. Braun, B. Braun is one of the world's leading healthcare suppliers. Their four divisions orient their products and services toward different medical fields: hospital, surgery, private practice (medical care and doctors' offices) and extra-corporeal blood treatment.

Registration web link (in German language)

About OpenText
OpenText is the leader in Enterprise Information Management (EIM). EIM enables organizations to grow the business, lower costs of operations, and reduce information governance and security related risks. OpenText focuses on the key drivers of business success to improve business insight, strengthen business impact, accelerate process velocity, address information governance and provide security.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Amgen to acquire Otezla® for $13.4 billion in cash

Amgen (NASDAQ: AMGN) announced today that it has entered into an agreement with Celgene Corporation (NASDAQ: CELG) in connection with its previously announced merger with...